898 related articles for article (PubMed ID: 21133840)
21. Modulation of TNFR 1-triggered two opposing signals for inflammation and apoptosis via RIPK 1 disruption by geldanamycin in rheumatoid arthritis.
Saeki Y; Okita Y; Igashira-Oguro E; Udagawa C; Murata A; Tanaka T; Mukai J; Miyazawa K; Hoshida Y; Ohshima S
Clin Rheumatol; 2021 Jun; 40(6):2395-2405. PubMed ID: 33415454
[TBL] [Abstract][Full Text] [Related]
22. Suppression of TNF-α and IL-1 signaling identifies a mechanism of homeostatic regulation of macrophages by IL-27.
Kalliolias GD; Gordon RA; Ivashkiv LB
J Immunol; 2010 Dec; 185(11):7047-56. PubMed ID: 20971923
[TBL] [Abstract][Full Text] [Related]
23. The antiinflammatory drug sulfasalazine inhibits tumor necrosis factor alpha expression in macrophages by inducing apoptosis.
Rodenburg RJ; Ganga A; van Lent PL; van de Putte LB; van Venrooij WJ
Arthritis Rheum; 2000 Sep; 43(9):1941-50. PubMed ID: 11014343
[TBL] [Abstract][Full Text] [Related]
24. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action.
Bourne T; Fossati G; Nesbitt A
BioDrugs; 2008; 22(5):331-7. PubMed ID: 18778114
[TBL] [Abstract][Full Text] [Related]
25. Tumor necrosis factor α induces sustained signaling and a prolonged and unremitting inflammatory response in rheumatoid arthritis synovial fibroblasts.
Lee A; Qiao Y; Grigoriev G; Chen J; Park-Min KH; Park SH; Ivashkiv LB; Kalliolias GD
Arthritis Rheum; 2013 Apr; 65(4):928-38. PubMed ID: 23335080
[TBL] [Abstract][Full Text] [Related]
26. Adam17 Deficiency Promotes Atherosclerosis by Enhanced TNFR2 Signaling in Mice.
Nicolaou A; Zhao Z; Northoff BH; Sass K; Herbst A; Kohlmaier A; Chalaris A; Wolfrum C; Weber C; Steffens S; Rose-John S; Teupser D; Holdt LM
Arterioscler Thromb Vasc Biol; 2017 Feb; 37(2):247-257. PubMed ID: 28062509
[TBL] [Abstract][Full Text] [Related]
27. Critical role of TNF-alpha-TNFR1 signaling in intracranial aneurysm formation.
Aoki T; Fukuda M; Nishimura M; Nozaki K; Narumiya S
Acta Neuropathol Commun; 2014 Mar; 2():34. PubMed ID: 24685329
[TBL] [Abstract][Full Text] [Related]
28. Tumor necrosis factor receptor pre-ligand assembly domain is an important therapeutic target in inflammatory arthritis.
Deng GM
BioDrugs; 2007; 21(1):23-9. PubMed ID: 17263587
[TBL] [Abstract][Full Text] [Related]
29. Anti-tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner.
Vos AC; Wildenberg ME; Duijvestein M; Verhaar AP; van den Brink GR; Hommes DW
Gastroenterology; 2011 Jan; 140(1):221-30. PubMed ID: 20955706
[TBL] [Abstract][Full Text] [Related]
30. Signal transduction by tumor necrosis factor and its relatives.
Baud V; Karin M
Trends Cell Biol; 2001 Sep; 11(9):372-7. PubMed ID: 11514191
[TBL] [Abstract][Full Text] [Related]
31. TNFR1 and TNFR2 differentially mediate TNF-α-induced inflammatory responses in rheumatoid arthritis fibroblast-like synoviocytes.
Zhang H; Xiao W
Cell Biol Int; 2017 Apr; 41(4):415-422. PubMed ID: 28150360
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab.
Mitoma H; Horiuchi T; Tsukamoto H; Tamimoto Y; Kimoto Y; Uchino A; To K; Harashima S; Hatta N; Harada M
Arthritis Rheum; 2008 May; 58(5):1248-57. PubMed ID: 18438840
[TBL] [Abstract][Full Text] [Related]
33. Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study.
Waljee AK; Higgins PDR; Jensen CB; Villumsen M; Cohen-Mekelburg SA; Wallace BI; Berinstein JA; Allin KH; Jess T
Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):276-284. PubMed ID: 31836320
[TBL] [Abstract][Full Text] [Related]
34. IFNγ potentiates TNFα/TNFR1 signaling to induce FAT10 expression in macrophages.
Kandel-Kfir M; Garcia-Milan R; Gueta I; Lubitz I; Ben-Zvi I; Shaish A; Shir L; Harats D; Mahajan M; Canaan A; Kamari Y
Mol Immunol; 2020 Jan; 117():101-109. PubMed ID: 31759325
[TBL] [Abstract][Full Text] [Related]
35. TRAPS mutations in
Akagi T; Hiramatsu-Asano S; Ikeda K; Hirano H; Tsuji S; Yahagi A; Iseki M; Matsuyama M; Mak TW; Nakano K; Ishihara K; Morita Y; Mukai T
Front Immunol; 2022; 13():926175. PubMed ID: 35936010
[TBL] [Abstract][Full Text] [Related]
36. Role of TNF-TNF Receptor 2 Signal in Regulatory T Cells and Its Therapeutic Implications.
Yang S; Wang J; Brand DD; Zheng SG
Front Immunol; 2018; 9():784. PubMed ID: 29725328
[TBL] [Abstract][Full Text] [Related]
37. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages.
Atreya R; Zimmer M; Bartsch B; Waldner MJ; Atreya I; Neumann H; Hildner K; Hoffman A; Kiesslich R; Rink AD; Rau TT; Rose-John S; Kessler H; Schmidt J; Neurath MF
Gastroenterology; 2011 Dec; 141(6):2026-38. PubMed ID: 21875498
[TBL] [Abstract][Full Text] [Related]
38. Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases.
LaDuca JR; Gaspari AA
Dermatol Clin; 2001 Oct; 19(4):617-35. PubMed ID: 11705350
[TBL] [Abstract][Full Text] [Related]
39. Expression of the angiogenic factor thymidine phosphorylase in THP-1 monocytes: induction by autocrine tumor necrosis factor-alpha and inhibition by aspirin.
Zhu GH; Schwartz EL
Mol Pharmacol; 2003 Nov; 64(5):1251-8. PubMed ID: 14573775
[TBL] [Abstract][Full Text] [Related]
40. The rationale for the current boom in anti-TNFalpha treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFalpha and minimise hazards?
Feldmann M; Bondeson J; Brennan FM; Foxwell BM; Maini RN
Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I27-31. PubMed ID: 10577970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
